...
机译:Lenalidomide与Bendamustine和Prednisolone联合复发/难治性多发性骨髓瘤:2阶段临床试验的结果(OSHO-#077)
Department of Haematology and Oncology University of Leipzig;
Haematology Practice;
Department of Haematology and Oncology Klinikum Südstadt Rostock;
Department of Haematology and Oncology University of Jena;
Haematology Practice;
Department of Haematology and Oncology University of Leipzig;
Department of Haematology and Oncology University of Rostock;
Department of Haematology and Oncology Johanniter Krankenhaus;
Haematology Practice;
Department of Haematology and Oncology Asklepios Hospital;
Department of Haematology and Oncology University of Leipzig;
Department of Haematology and Oncology Hospital Johann Kentmann;
Haematology Practice;
Department of Haematology and Oncology Heinrich-Braun-Hospital;
Department of Haematology and Oncology Paul Gerhardt Stift;
Haematology Practice;
Department of Haematology and Oncology University of Leipzig;
Department of Haematology and Oncology University of Leipzig;
Department of Haematology and Oncology University of Leipzig;
Department of Haematology and Oncology University of Leipzig;
Department of Haematology and Oncology University of Leipzig;
Department of Haematology and Oncology University of Leipzig;
Relapsed/refractory multiple myeloma; Lenalidomide; Bendamustine; Prednisolone; Phase 2 study;
机译:Lenalidomide与Bendamustine和Prednisolone联合复发/难治性多发性骨髓瘤:2阶段临床试验的结果(OSHO-#077)
机译:来那度胺,苯达莫司汀和泼尼松龙在复发或难治性多发性骨髓瘤中显示出良好的安全性和疗效:OSHO-1期临床试验的最终结果
机译:自体干细胞移植或常规化疗后联合苯达莫司汀,泼尼松龙和沙利度胺治疗难治性或复发性多发性骨髓瘤:I期临床试验的结果。
机译:在临床试验中治疗多发性骨髓瘤
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:苯达莫司汀来那度胺和地塞米松(BLD)在复发或难治性多发性骨髓瘤患者中的组合是可行和高效的:1/2期开放标签剂量递增研究的结果
机译:在用Lenalidomide和Bortezomib治疗后,研究II期试验,以研究弯曲蛋白,地塞米松,摩天蛋白酶,地塞米松和沙利度族的疗效和安全性复发或难治多骨髓瘤患者